Drug Search Results
More Filters [+]

Nivocasan

Alternative Names: nivocasan, gs-9450, gs9450, gs 9450
Latest Update: 2023-09-12
Latest Update Note: News Article

Product Description

Mechanisms of Action: CAAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nivocasan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Communicable Diseases|Hepatitis C, Chronic|Liver Cirrhosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-007456-96

P2

Completed

Hepatitis C, Chronic

2010-07-20

GS-US-227-0106

P2

Terminated

Hepatitis C, Chronic|Communicable Diseases

2010-04-01

2008-002361-31

P2

Completed

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2009-08-05

GS-US-228-0101

P2

Completed

Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic

2009-08-01

Recent News Events